

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8375271/publications.pdf>

Version: 2024-02-01

136
papers

43,440
citations

19636

61
h-index

13365

130
g-index

136
all docs

136
docs citations

136
times ranked

29555
citing authors

#	ARTICLE	IF	CITATIONS
1	Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2020, 382, 1894-1905.	13.9	3,828
2	Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. <i>Lancet, The</i> , 2018, 391, 1163-1173.	6.3	3,542
3	Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2018, 68, 723-750.	3.6	3,096
4	AASLD guidelines for the treatment of hepatocellular carcinoma. <i>Hepatology</i> , 2018, 67, 358-380.	3.6	2,932
5	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 56-66.	6.3	2,771
6	Hepatocellular carcinoma. <i>Nature Reviews Disease Primers</i> , 2021, 7, 6.	18.1	2,757
7	Palbociclib and Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1925-1936.	13.9	1,943
8	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <i>Lancet Oncology, The</i> , 2018, 19, 940-952.	5.1	1,816
9	The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. <i>Lancet Oncology, The</i> , 2015, 16, 25-35.	5.1	1,574
10	Molecular therapies and precision medicine for hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 599-616.	12.5	1,308
11	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 193-202.	0.8	1,255
12	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2019, 20, 282-296.	5.1	1,202
13	PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. <i>Breast Cancer Research</i> , 2009, 11, R77.	2.2	1,131
14	Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells. <i>Cancer Research</i> , 2006, 66, 1630-1639.	0.4	846
15	Treating cancer with selective CDK4/6 inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 417-430.	12.5	806
16	Immunotherapies for hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 151-172.	12.5	643
17	Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 76, 862-873.	1.8	568
18	Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3509-3516.	0.8	544

#	ARTICLE	IF	CITATIONS
19	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 77-90.	5.1	526
20	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282.	0.8	524
21	Advances in targeted therapies for hepatocellular carcinoma in the genomic era. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 408-424.	12.5	456
22	Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 5544-5552.	0.8	407
23	Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening. <i>Cancer Cell</i> , 2011, 19, 347-358.	7.7	379
24	Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/â€œtriple-negativeâ€•breast cancer cell lines growing in vitro. <i>Breast Cancer Research and Treatment</i> , 2007, 105, 319-326.	1.1	369
25	Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. <i>Oncogene</i> , 1998, 17, 2235-2249.	2.6	353
26	The Role of Angiogenesis in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 912-920.	3.2	345
27	Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. <i>Hepatology</i> , 2005, 41, 1130-1137.	3.6	333
28	The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. <i>Oncogene</i> , 1997, 15, 537-547.	2.6	317
29	Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. <i>Hepatology</i> , 2014, 60, 1697-1707.	3.6	279
30	Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. <i>Journal of Hepatology</i> , 2018, 69, 353-358.	1.8	270
31	Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. <i>Breast Cancer Research</i> , 2016, 18, 17.	2.2	257
32	Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, 1460-1469.	1.8	254
33	Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 1591-1602.	3.2	247
34	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. <i>Hepatology</i> , 2021, 73, 158-191.	3.6	235
35	IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 267-267.	0.8	226
36	Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244). <i>Cancer Research</i> , 2010, 70, 2264-2273.	0.4	222

#	ARTICLE	IF	CITATIONS
37	SRC: A Century of Science Brought to the Clinic. <i>Neoplasia</i> , 2010, 12, 599-607.	2.3	190
38	Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. <i>Nature Medicine</i> , 2022, 28, 1599-1611.	15.2	185
39	Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study. <i>Clinical Cancer Research</i> , 2011, 17, 6905-6913.	3.2	183
40	Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 991-1001.	5.1	179
41	Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis. <i>Hepatology</i> , 2018, 67, 422-435.	3.6	177
42	Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 2090-2098.	3.2	167
43	Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3908-3915.	0.8	154
44	Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 1973-1983.	3.2	142
45	Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. <i>Breast Cancer Research</i> , 2016, 18, 67.	2.2	140
46	A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6614-6623.	3.2	139
47	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. <i>Cancer Treatment Reviews</i> , 2018, 68, 16-24.	3.4	124
48	Current approaches and future directions in the treatment of HER2-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 219-229.	3.4	120
49	Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 110-121.	3.2	120
50	Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4071-4071.	0.8	107
51	A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4076-4076.	0.8	101
52	Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT. <i>Clinical Cancer Research</i> , 2014, 20, 3507-3520.	3.2	100
53	Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?. <i>Clinical Cancer Research</i> , 2010, 16, 390-397.	3.2	98
54	Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 503-509.	1.1	96

#	ARTICLE	IF	CITATIONS
55	Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.. Journal of Clinical Oncology, 2019, 37, TPS4152-TPS4152.	0.8	94
56	REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.. Journal of Clinical Oncology, 2018, 36, 4003-4003.	0.8	77
57	Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2~ advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Research and Treatment, 2020, 183, 419-428.	1.1	73
58	Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib. Molecular Cancer Therapeutics, 2012, 11, 1978-1987.	1.9	68
59	The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non~Small Cell Lung Cancer Growth. Molecular Cancer Therapeutics, 2013, 12, 890-900.	1.9	67
60	Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 1271-1277.	1.8	66
61	Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer, 2012, 1, 247-256.	4.2	65
62	Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2~ metastatic breast cancer in US real-world clinical practice. Breast Cancer Research, 2021, 23, 37.	2.2	65
63	Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 93-104.	4.2	60
64	Identification of Common Predictive Markers of <i>in vitro</i> Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non~Small Cell Lung Cancer Cell Lines. Molecular Cancer Therapeutics, 2010, 9, 1985-1994.	1.9	59
65	Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non~Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 270-278.	0.5	59
66	Palbociclib plus endocrine therapy in older women with HR+/HER2~ advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. European Journal of Cancer, 2018, 101, 123-133.	1.3	59
67	Emerging Targeted Strategies in Advanced Hepatocellular Carcinoma. Seminars in Liver Disease, 2013, 33, S11-S19.	1.8	58
68	Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-Advanced Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 419-430.	3.0	55
69	Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. Liver International, 2009, 29, 284-290.	1.9	53
70	IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.. Journal of Clinical Oncology, 2021, 39, 4073-4073.	0.8	52
71	Prognostic and Predictive Value of HER2 Extracellular Domain in Metastatic Breast Cancer Treated With Lapatinib and Paclitaxel in a Randomized Phase III Study. Journal of Clinical Oncology, 2009, 27, 5552-5558.	0.8	49
72	Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2~ Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. Oncologist, 2019, 24, 1514-1525.	1.9	49

#	ARTICLE	IF	CITATIONS
73	Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines<i>in vitro</i>. <i>Hepatology</i> , 2013, 57, 1838-1846.	3.6	46
74	In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 669-680.	1.1	46
75	Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection. <i>Liver Cancer</i> , 2016, 5, 221-232.	4.2	44
76	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
77	Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. <i>European Journal of Cancer</i> , 2022, 167, 1-12.	1.3	43
78	Clinical Review on the Management of Hormone Receptorâ€“Positive Metastatic Breast Cancer. <i>JCO Oncology Practice</i> , 2022, 18, 319-327.	1.4	40
79	Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study. <i>BMC Cancer</i> , 2012, 12, 16.	1.1	39
80	Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study. <i>Clinical Cancer Research</i> , 2021, 27, 4848-4858.	3.2	39
81	IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4141-TPS4141.	0.8	38
82	Monoclonal antibody therapy for breast cancer: Herceptin. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003, 21, 223-233.	0.5	36
83	Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT).. <i>Journal of Clinical Oncology</i> , 2019, 37, 186-186.	0.8	35
84	Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. <i>Journal of Global Oncology</i> , 2019, 5, 1-19.	0.5	34
85	Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. <i>Anti-Cancer Drugs</i> , 2018, 29, 271-280.	0.7	33
86	Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5â€“Years of Follow-Up. <i>Oncologist</i> , 2021, 26, e749-e755.	1.9	33
87	Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab. <i>PLoS ONE</i> , 2013, 8, e56112.	1.1	32
88	Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2547-2554.	3.2	32
89	Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 1159-1173.	1.0	30
90	KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.. <i>Journal of Clinical Oncology</i> , 2018, 36, 209-209.	0.8	30

#	ARTICLE	IF	CITATIONS
91	Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. <i>Liver International</i> , 2020, 40, 2008-2020.	1.9	26
92	Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).. <i>Journal of Clinical Oncology</i> , 2019, 37, 317-317.	0.8	26
93	Brivanib: a review of development. <i>Future Oncology</i> , 2012, 8, 1083-1090.	1.1	25
94	Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 736-743.	3.2	25
95	Management of ER positive metastatic breast cancer. <i>Seminars in Oncology</i> , 2020, 47, 270-277.	0.8	25
96	Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. <i>Breast Cancer Research</i> , 2020, 22, 27.	2.2	24
97	Drug therapy: Sorafenib. <i>Hepatology</i> , 2010, 51, 1843-1849.	3.6	23
98	What's positive about triple-negative breast cancer?. <i>Future Oncology</i> , 2009, 5, 1015-1025.	1.1	22
99	AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 397-408.	1.1	21
100	Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2014, 3, 439-450.	4.2	21
101	Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. <i>Clinical Breast Cancer</i> . 2020, 20, e173-e180.	1.1	21
102	Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 23-35.	1.1	21
103	IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4071-4071.	0.8	21
104	Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells. <i>Cancer Research</i> , 2016, 76, 5822-5831.	0.4	20
105	Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib. <i>Targeted Oncology</i> , 2021, 16, 69-76.	1.7	19
106	Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies. <i>Clinical Cancer Research</i> , 2022, 28, 3443-3451.	3.2	19
107	Systemic therapy in HCC: Lessons from brivanib. <i>Journal of Hepatology</i> , 2014, 61, 947-950.	1.8	18
108	CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 483-483.	0.8	17

#	ARTICLE	IF	CITATIONS
109	Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. <i>Hepatic Oncology</i> , 2014, 1, 181-188.	4.2	16
110	Lapatinib, a Dual-Targeted Small Molecule Inhibitor of EGFR and HER2, in HER2-Amplified Breast Cancer: From Bench to Bedside. <i>Clinical Medicine Insights Therapeutics</i> , 2011, 3, CMT.S3783.	0.4	13
111	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. <i>Liver International</i> , 2021, 41, 598-607.	1.9	13
112	Abstract P1-19-02: Overall survival for first-line palbociclib plus letrozole vs letrozole alone for HR+/HER2- metastatic breast cancer patients in US real-world clinical practice. , 2020, , .		13
113	Subsequent anticancer medication following first-line lenvatinib: A posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 371-371.	0.8	10
114	Systemic Therapy for Primary Liver Tumors. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 695-715.	0.6	9
115	Survival after sorafenib: Expect the unexpected. <i>Journal of Hepatology</i> , 2014, 60, 243-244.	1.8	8
116	Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptorâ€positive/human epidermal growth factor receptor 2â€negative metastatic breast cancer. <i>Breast Journal</i> , 2020, 26, 368-375.	0.4	8
117	Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. <i>Clinical Cancer Research</i> , 2022, 28, 2297-2305.	3.2	8
118	Sorafenib use while waiting for liver transplant: We still need to wait. <i>Journal of Hepatology</i> , 2012, 56, 723-725.	1.8	7
119	Progression-free survival: Starting point or endpoint in advanced HCC trial design?. <i>Journal of Hepatology</i> , 2019, 70, 1062-1064.	1.8	7
120	Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4596-4596.	0.8	7
121	Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. <i>Journal of Gastroenterology</i> , 2021, 56, 570-580.	2.3	6
122	IMbrave150: Exploratory efficacy and safety in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab beyond radiological progression until loss of clinical benefit in a global phase III study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 470-470.	0.8	6
123	Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). <i>Liver Cancer</i> , 2021, 10, 451-460.	4.2	5
124	Continuous-dose regorafenib (REG) in hepatocellular carcinoma (HCC): Phase I safety and pharmacokinetic (PK) study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 300-300.	0.8	5
125	Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2013, 9, 1-24.	0.2	5
126	The Place of Novel Therapies in the American Association for the Study of Liver Diseases Guidelines for Hepatocellular Carcinoma. <i>Clinical Liver Disease</i> , 2019, 14, 51-55.	1.0	4

#	ARTICLE	IF	CITATIONS
127	Covalent Chemistry-Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular Carcinoma. <i>Advanced Materials Technologies</i> , 2021, 6, 2001056.	3.0	4
128	Current State of Immunotherapy for HCC—Supporting Data and Toxicity Management. <i>Current Hepatology Reports</i> , 2018, 17, 434-443.	0.4	2
129	Subsequent anticancer procedures following first-line lenvatinib (LEN): A post hoc analysis from the phase III REFLECT study in unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 520-520.	0.8	2
130	HER2-positive breast cancer: trastuzumab, lapatinib and emerging therapies. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2012, 9, e55-e60.	0.5	1
131	Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 345-345.	0.8	1
132	Safety and efficacy of lenvatinib by starting dose (8 mg or 12 mg) based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.. <i>Journal of Clinical Oncology</i> , 2019, 37, 316-316.	0.8	1
133	Abstract CT523: An open-label, multicenter, phase 1b/2 Study of E7386 (Wnt/ β^2 -catenin pathway inhibitor) + pembrolizumab in patients with pretreated advanced solid tumors. <i>Cancer Research</i> , 2022, 82, CT523-CT523.	0.4	1
134	Biologic and Systemic Therapies for the Treatment of Hepatocellular Carcinoma. , 2013, , 363-372.		0
135	Overcoming Treatment Resistance in Hepatocellular Carcinoma: Regorafenib and Lessons from Other Malignancies. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2017, , 133-142.	0.1	0
136	Characterization of tumor responses in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib in REFLECT.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4078-4078.	0.8	0